Skip to main content
SpringerLink
Log in
Book cover

Cancer du sein : surdiagnostic, surtraitement pp 125–129Cite as

Pas d’hormonothérapie pour quels cancers RH (+)?

Is hormonal therapy mandatory for hormone-responsive patients in adjuvant setting?

  • Conference paper

  • 224 Accesses

Résumé

L’hormonothérapie adjuvante chez les patientes RH+ est souvent considérée comme obligatoire [1]. Elle répond aux critères actuellement requis dans cette indication : efficacité démontrée, bonne tolérance globale, facteur prédictif reconnu.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Rabaglio M, Aebi S, Castiglione-Gertsch M (2007) Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncology 940–949

    Google Scholar 

  2. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  Google Scholar 

  3. EBCTCG (2011) Relevance of breast cancer hormone receptors and other factors to the efficacity of adjuvant tamoxifen: patient level meta-analysis of randomised trials. Lancet (in press)

    Google Scholar 

  4. Lin NU, Winer E (2008) Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol 26: 1919–1921

    Article  PubMed  Google Scholar 

  5. Hazel B, Nichols HB, Berrington De Gonzalez A, Lacey Jr J.V, Rosenberg PS, Anderson WF (2011) Declining incidence of controlateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29: 1564–1569

    Article  Google Scholar 

  6. Goss PE, Ingle JN, Ales-Martinez JE et al. (2011) Exemestane for breast-cancer prevention in postmenopausal women. New Engl J Med 364: 2381–2391

    Article  PubMed  CAS  Google Scholar 

  7. Hackshaw A, Roughton M, Forsyth S et al. (2011) Long-term benefits of 5 years of Tamoxifen: 10 year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 29: 1657–63

    Article  PubMed  Google Scholar 

  8. Morgan DAL, Refalo NA, Cheung KL (2011) Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. The Breast 20: 215–219

    Article  PubMed  Google Scholar 

  9. The ATAC trialists’group (2008) Effects of Anastrozole and Tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9: 45–53

    Article  Google Scholar 

  10. Van De Velde CJH, Rea D, Seynaeve C et al. (2011) Adjuvant Tamoxifen and Exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377: 321–331

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale Centre Eugène Marquis, CS 44229, Université Rennes, 35042, Rennes Cedex

    P. Kerbrat, C. Perrin, J. Edeline & M. Talarmin

Authors
  1. P. Kerbrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Perrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Edeline
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Talarmin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this paper

Cite this paper

Kerbrat, P., Perrin, C., Edeline, J., Talarmin, M. (2012). Pas d’hormonothérapie pour quels cancers RH (+)?. In: Cancer du sein : surdiagnostic, surtraitement. Springer, Paris. https://doi.org/10.1007/978-2-8178-0249-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0249-7_22

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0248-0

  • Online ISBN: 978-2-8178-0249-7

Publish with us

Policies and ethics

Search

Navigation